Abstract:Xiaojie Yan, 1, &ast Xueying Zhao, 2, &ast Mingde Fan, 3 Wenfu Zheng, 4, 5 Guanxiong Zhu, 6 Bin Li, 1 Le Wang 1 1 Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China; 2 Department of Transfusion, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China; 3 Department of Neurosurgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China; 4 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for NanoScience and Technology, Beijing, People's Republic of China; 5 School of Nanoscience and Engineering, University of Chinese Academy of Sciences, Beijing, People's Republic of China; 6 Department of Preventive Dentistry, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Le Wang; Bin Li, Academician Workstation, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, People's Republic of China, Tel/Fax +86-791-86362367, Email ; Background: Dihydroartemisinin (DHA) has emerged as a promising candidate for anticancer therapy. However, the application of DHA in clinics has been hampered by several limitations including poor bioavailability, short circulation life, and low solubility, significantly restricting its therapeutic efficacy and leading to notable side effects during the treatment. Purpose: We present DHA-loaded zeolitic imidazolate framework-8 (D-ZIF) with controllable and targeted DHA release properties, leading to enhanced antitumor effects while reducing potential side effects. Methods: D-ZIF was prepared by one-pot synthesis method using methylimidazole (MIM), Zn(NO 3 ) 2 • 6H 2 O and DHA. We characterized the physical and chemical properties of D-ZIF by TEM, DLS, XRD, FT-IR, and TG. We measured the drug loading efficiency and the cumulative release of DHA in different pH conditions. We evaluated the cytotoxicity of D-ZIF on renal cell carcinoma (RCC786-O), glioma cells (U251), TAX-resistant human lung adenocarcinoma (A549-TAX) cells by CCK8 in vitro. We explored the possible antitumor mechanism of D-ZIF by Western blot. We evaluated the biocompatibility and hemolysis of D-ZIF and explored the in vivo antitumor efficiency in mice model by TUNEL testing and blood biomarker evaluations. Results: D-ZIF showed rhombic dodecahedral morphology with size of 129± 7.2 nm and possessed a noticeable DHA encapsulation efficiency (72.9%). After 48 hours, D-ZIF released a cumulative 70.0% of the loaded DHA at pH 6.5, and only 42.1% at pH 7.4. The pH-triggered programmed release behavior of D-ZIF could enhance anticancer effect of DHA while minimizing side effects under normal physiological conditions. Compared with the free DHA group with 31.75% of A549-TAX cell apoptosis, the percentage of apoptotic cells was approximately 76.67% in the D-ZIF group. D-ZIF inhibited tumor growth by inducing tumor cell apoptosis through the mechanism of ROS production and regulation of Nrf2/HO-1 and P38 MAPK signaling pathways. D-ZIF showed potent effects in treating tumors with high safety in vivo. Conclusion: This pH-responsive release mechanism enhanced the targeting efficiency of DHA towards tumor cells, thereby increasing drug concentration in tumor sites with negligible side effects. Herein, D-ZIF holds great promise for curing cancers with minimal adverse effects. Keywords: MOF, drug delivery, controlled release, cancer therapy Cancers especially lung cancer pose a significant threat to human health. 1–3 For a considerable duration, patients facing cancers had limited options for treatment, primarily relying on surgery, radiation therapy, and chemotherapy, either individually or in combination. 4 A significant challenge associated with chemotherapy is the development of drug resistance. 5 Multi-drug resistance (MDR) in cancer cells, whether intrinsic or acquired, leads to reduced drug absorption and increased drug efflux, representing a substantial obstacle to the therapeutic effectiveness of drugs. In tackling these challenges, nanotechnology-based delivery systems have demonstrated the ability to provide controlled and targeted delivery, 6 thereby enhancing the intracellular availability of drugs and exploring opportunities to overcome MDR. 7 Recently, the active derivatives of traditional Chinese medicine have emerged as c -Abstract Truncated-

Bioinspired Microenvironment Responsive Nanoprodrug as an Efficient Hydrophobic Drug Self-Delivery System for Cancer Therapy

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy

NIR-responsive polydopamine-based calcium carbonate hybrid nanoparticles delivering artesunate for cancer chemo-photothermal therapy

Acidic Environment-Responsive Metal Organic Framework-Mediated Dihydroartemisinin Delivery for Triggering Production of Reactive Oxygen Species in Drug-Resistant Lung Cancer

Pharmacophore Hybridisation and Nanoscale Assembly to Discover Self-Delivering Lysosomotropic New-Chemical Entities for Cancer Therapy

Tumor Microenvironment-Responsive Biodegradable Nanomedicine for Self-Enhanced Synergistic Chemo-, Photothermal, and Chemodynamic Therapy

Glutathione-Responsive Multifunctional “Trojan Horse” Nanogel as a Nanotheranostic for Combined Chemotherapy and Photodynamic Anticancer Therapy

A Self-Disguised Nanospy for Improving Drug Delivery Efficiency via Decreasing Drug Protonation

Smart Nanoplatform with Programmed Release of Dihydroartemisinin and Fe 2+ Self-Supply for Synergistic Cancer Therapy

Microfluidics-Assisted Surface Trifunctionalization of a Zeolitic Imidazolate Framework Nanocarrier for Targeted and Controllable Multitherapies of Tumors

Acidity-Triggered Charge-Convertible Conjugated Polymer for Dihydroartemisinin Delivery and Tumor-Specific Chemo-Photothermal Therapy.

Near-Infrared-Controlled, Targeted Hydrophobic Drug-Delivery System for Synergistic Cancer Therapy

Biomimetic Nucleation of Metal–Organic Frameworks on Silk Fibroin Nanoparticles for Designing Core–Shell-Structured pH-Responsive Anticancer Drug Carriers

A self-assembled copper-artemisinin nanoprodrug as an efficient reactive oxygen species amplified cascade system for cancer treatment

Empowering hydrophobic anticancer drugs by ultrashort peptides: General Co-assembly strategy for improved solubility, targeted efficacy, and clinical application

K. ZHENG ET AL.Gold-nanoparticle-based multistage drug delivery system for antitumor therapy

A drug ligand based bimetallic coordination-driven self-assembly nanodrug for high-efficiency tumor chemodynamic therapy

pH/Redox/Lysozyme-Sensitive Hybrid Nanocarriers With Transformable Size for Multistage Drug Delivery

Nanoscale Metal-Organic-Frameworks Coated by Biodegradable Organosilica for Ph and Redox Dual Responsive Drug Release and High-Performance Anticancer Therapy.